Abstract:O‐linked N ‐acetylglucosamine (O‐GlcNAc) is a highly dynamic post‐translational modification that involves an addition of a single N‐ acetylglucosamine to serine and threonine residue in mitochondria, nuclear and cytoplasmic proteins. O‐GlcNAc cycling is the addition and removal of O‐GlcNAc by O‐GlcNAc transferase (OGT) and O‐GlcNAcase (OGA) respectively. Disruptions in O‐GlcNAc cycling contribute to diseases such as diabetes, cancer, and neurodegeneration. Accumulative dysfunctional mitochondria can also lead to the development of neurodegenerative diseases, and importantly, O‐GlcNAcylation regulates mitochondrial function. Previously, using a proteomics based screen we found that altering the expression of OGT and OGA disrupted mitochondrial protein expression, including proteins involved in the respiratory chain and TCA cycle. Furthermore, mitochondrial morphology in the over‐expressing cells had reduced and disorganized cristae and altered shape and size. Both cellular respiration and glycolysis was impaired in the OGT/OGA gain of function cells. These data suggested that O‐GlcNAc cycling was essential for the proper regulation of mitochondrial function. We hypothesized that prolonged elevations in cellular O‐GlcNAc levels would alter the metabolic profile of the cell. We disrupted O‐GlcNAc cycling by either treating SH‐SY5Y neuroblastoma cells with low levels of Glucosamine (GlcN) or OGA inhibitor Thiamet‐G (TMG). Importantly, the metabolic substrate for O‐GlcNAcylation is UDP‐GlcNAc. UDP‐GlcNAc is synthesized via the hexosamine biosynthetic pathway, which is highly sensitive towards the availability of nutrients in the cellular environment. GlcN feeds into the hexosamine biosynthetic pathway after the first rate‐limiting enzyme GFAT1, glutamine fructose‐6‐phosphate aminotransferase 1, and additional supplementation of GlcN increases O‐GlcNAcylation via elevating the synthesis of UDP‐GlcNAc. We found that prolonged TMG/GlcN treatment improved mitochondrial function. In the TMG/GlcN treated cells, reactive oxygen species (ROS) production was significantly reduced. Interestingly, the protein expression of the mitochondrial antioxidant, manganese superoxide dismustase (MnSOD) was lower. Additionally, ATP production was lower in these TMG/GlcN treated cells. Furthermore, we found that mitochondrial were longer in shape and mitochondrial fusion/fission protein expressions were decreased. Altogether, these data demonstrated that prolonged alterations to the cellular homeostasis of O‐GlcNAc levels improve mitochondrial function likely through reprogramming of metabolic transcriptional programs. Further understanding of how O‐GlcNAc cycling regulates metabolism will provide new insights into metabolic diseases such as cancer and Alzheimer's. Support or Funding Information RO1DK100595

N-glycanase NGLY1 Regulates Mitochondrial Homeostasis and Inflammation Through NRF1

N-Glycanase 1 Deficiency Triggers Innate Immune Activation Through Dysregulated Mitophagy

Comparative proteomics reveals elevated CCN2 in NGLY1-deficient cells

Doubling of Optic Disc

Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency

Functional Impact of Nth-like DNA glycosylase on Mitochondrial Dynamics

O‐GlcNAc is Critical for the Regulation of Energy Metabolism

Microglial Glutaminase 1 Deficiency Mitigates Neuroinflammation Associated Depression.

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

A full spectrum PNGase activity analysis of R328 mutations on NGLY1

Mitochondrial general control of amino acid synthesis 5 like 1 promotes nonalcoholic steatohepatitis development through ferroptosis‐induced formation of neutrophil extracellular traps

Dysfunction of the energy sensor NFE2L1 triggers uncontrollable AMPK signaling and glucose metabolism reprogramming

The Role of N-Glycan Modification of Tnfr1 in Inflammatory Microglia Activation

Glycerol-3-phosphate biosynthesis regenerates cytosolic NAD+ to alleviate mitochondrial disease

Elevated O‐GlcNAcylation levels improve mitochondrial function

Dntp Catabolism is a Macrophage-Intrinsic Gatekeeper Preventing NLRP3 Inflammasome Hyperactivation

Development of new NGLY1 assay systems - toward developing an early screening method for NGLY1 deficiency

Development of a Fluorescence and Quencher-based FRET Assay for Detection of Endogenous Peptide:N-glycanase/NGLY1 Activity

Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency

Functional Prediction of the Potential NGLY1 Mutations Associated with Rare Disease CDG